Medizinische Klinik V (Nephrologie, Hypertensiologie, Rheumatologie, Endokrinologie, Diabetelogie), Medizinische Fakultät Mannheim der Universität Heidelberg, Heidelberg, Germany.
Klinisches Institut für Medizinische und Chemische Labordiagnostik, Medizinische Universität Graz, Graz, Austria.
Clin Res Cardiol. 2017 Sep;106(9):663-675. doi: 10.1007/s00392-017-1106-1. Epub 2017 Mar 24.
While several lines of evidence prove that elevated concentrations of low-density lipoproteins (LDL) causally contribute to the development of atherosclerosis and its clinical consequences, high-density lipoproteins are still widely believed to exert atheroprotective effects. Hence, HDL cholesterol (HDL-C) is in general still considered as "good cholesterol". Recent research, however, suggests that this might not always be the case and that a fundamental reassessment of the clinical significance of HDL-C is warranted.
This review article is based on a selective literature review.
In individuals without a history of cardiovascular events, low concentrations of HDL-C are inversely associated with the risk of future cardiovascular events. This relationship may, however, not apply to patients with metabolic disorders or manifest cardiovascular disease. The classical function of HDL is to mobilise cholesterol from extrahepatic tissues for delivery to the liver for excretion. These roles in cholesterol metabolism as well as many other biological functions of HDL particles are dependent on the number as well as protein and lipid composition of HDL particles. They are poorly reflected by the HDL-C concentration. HDL can even exert negative vascular effects, if its composition is pathologically altered. High serum HDL-C is therefore no longer regarded protective. In line with this, recent pharmacological approaches to raise HDL-C concentration have not been able to show reductions of cardiovascular outcomes.
In contrast to LDL cholesterol (LDL-C), HDL-C correlates with cardiovascular risk only in healthy individuals. The calculation of the ratio of LDL-C to HDL-C is not useful for all patients. Low HDL-C should prompt examination of additional metabolic and inflammatory pathologies. An increase in HDL-C through lifestyle change (smoking cessation, physical exercise) has positive effects and is recommended. However, HDL-C is currently not a valid target for drug therapy.
虽然有几条证据表明,低密度脂蛋白(LDL)浓度升高与动脉粥样硬化的发生及其临床后果有因果关系,但高密度脂蛋白(HDL)仍被广泛认为具有抗动脉粥样硬化作用。因此,通常仍认为 HDL 胆固醇(HDL-C)为“好胆固醇”。然而,最近的研究表明,情况并非总是如此,有必要重新评估 HDL-C 的临床意义。
本文基于选择性文献综述。
在无心血管事件病史的个体中,HDL-C 浓度低与未来心血管事件风险呈负相关。然而,这种关系可能不适用于代谢紊乱或有明显心血管疾病的患者。HDL 的经典功能是将胆固醇从肝外组织动员起来,输送到肝脏进行排泄。这些在胆固醇代谢中的作用以及 HDL 颗粒的许多其他生物学功能都依赖于 HDL 颗粒的数量以及蛋白质和脂质组成。而 HDL-C 浓度并不能很好地反映这些作用。如果 HDL 的组成发生病理性改变,甚至可能产生负面的血管作用。因此,高血清 HDL-C 不再被认为具有保护作用。与此一致的是,最近提高 HDL-C 浓度的药物治疗方法未能显示出心血管结局的降低。
与 LDL 胆固醇(LDL-C)不同,HDL-C 仅在健康个体中与心血管风险相关。计算 LDL-C 与 HDL-C 的比值对于所有患者并不都有用。低 HDL-C 应促使检查其他代谢和炎症性病理。通过生活方式改变(戒烟、体育锻炼)增加 HDL-C 具有积极作用,并建议采用。然而,HDL-C 目前不是药物治疗的有效靶点。